Aerovate Therapeutics, Inc. Uncategorized Contracts & Agreements
11 Contracts & Agreements
- Amendment No. 1 to Antibody Discovery and Option Agreement, dated as of September 27, 2024 (Filed With SEC on December 3, 2024)
- Offer Letter between Jade Biosciences, Inc. and Hetal Kocinsky, dated as of September 3, 2024 (Filed With SEC on December 3, 2024)
- Antibody Discovery and Option agreement, dated July 24, 2024, by and between Paragon Therapeutics, Inc., Parade Biosciences Holding, LLC and Jade Biosciences, Inc (Filed With SEC on December 3, 2024)
- Offer Letter between Jade Biosciences, Inc. and Elizabeth Balta, dated as of October 21, 2024 (Filed With SEC on December 3, 2024)
- Offer Letter between Jade Biosciences, Inc. and Andrew King, dated as of July 31, 2024 (Filed With SEC on December 3, 2024)
- Offer Letter between Jade Biosciences, Inc. and Jonathan Quick, dated as of August 29, 2024 (Filed With SEC on December 3, 2024)
- Offer Letter between Jade Biosciences, Inc. and Tom Frohlich, dated as of August 20, 2024 (Filed With SEC on December 3, 2024)
- Description of Securities (Filed With SEC on March 30, 2022)
- Offer Letter between the Registrant and Ralph Niven, dated April 26, 2020 (Filed With SEC on June 9, 2021)
- Offer Letter between the Registrant and Hunter Gillies, dated April 27, 2020 (Filed With SEC on June 9, 2021)
- Offer Letter between the Registrant and Benjamin T. Dake, dated November 4, 2019 (Filed With SEC on June 9, 2021)
